We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.
Add this topic to your myFT Digest for news straight to your inbox
Former Genzyme chief helped make ‘orphan’ drugs viable
Infusion promises improvement but symptoms are likely to persist
Scientific advances and legal incentives have encouraged investment
In Mexico, gaining access to treatment is the first battle for children with genetic disorders
French pharma group ready to pay $20bn for targets as it hunts sources of growth
Competition in the insulin market is hurting. So are rumours about the management
Burst of dealmaking keeps things interesting in healthcare’s Silicon Valley
Drugmaker curbs redundancy plan under political pressure
Vertex therapy could be multibillion-dollar product
The second best performer on the FTSE 100
Kevin Lilley of Old Mutual picks out investment themes for the eurozone
Consolidation of Genzyme expected to provide boost
German engineering group has played the M&A game well
International Edition
